Market Closed -
Nasdaq
01:30:00 04/06/2024 am IST
5-day change
1st Jan Change
4.26
USD
0.00%
+3.40%
-43.65%
PetMed Express, Inc. : Close to an important medium term support level Entry price Target Stop-loss Potential
US$31.53
US$35.7
US$30
+13.23%
The support at 30.73 USD, which is currently being tested, should allow PetMed Express, Inc. shares to move back to the upside.
Summary ● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths ● The share is getting closer to its long-term support in weekly data, at USD 29.01, which offers good timing for buyers.
● Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 28.96 support.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● Historically, the company has been releasing figures that are above expectations.
● The company is one of the best yield companies with high dividend expectations.
PetMed Express, Inc. Announces Executive Changes
03/06
CI
PetMed Express, Inc. Announces Christine Chambers Will Leave the Company in Early August 2024
03/06
CI
PetMed Express, Inc. Appoints Carla Dodds as Chief Marketing Officer
28/05
CI
Petmed Express, Inc. Appoints Justin Mennen to Board of Directors, Effective June 3, 2024
20/05
CI
PetMed Express, Inc. Announces Executive Changes
29/04
CI
Petmed Express, Inc. Announces CEO Changes
29/04
CI
PetMed Express Appoints Sandra Campos as Chief Executive, President
29/04
MT
Earnings Flash (PETS) PETMED EXPRESS Posts Q3 Revenue $65.3M
15/04
MT
PetMed Express, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
15/04
CI
PetMed Express, Inc.(NasdaqGS:PETS) dropped from NASDAQ Internet Index
15/03
CI
Transcript : PetMed Express, Inc., Q3 2024 Earnings Call, Feb 08, 2024
09/02
PetMed Express Names Leslie C. G. Campbell Chairman
09/01
MT
PetMed Express, Inc. Announces Management Changes
09/01
CI
Morgan Stanley Trims Price Target on PetMed Express to $6.50 From $7, Keeps Underweight Rating
16/11
MT
Petmed Express Insider Bought Shares Worth $301,125, According to a Recent SEC Filing
13/11
MT
Petmed Express Insider Bought Shares Worth $100,551, According to a Recent SEC Filing
08/11
MT
Tranche Update on PetMed Express, Inc.'s Equity Buyback Plan announced on August 1, 2011.
01/23/01
CI
Traders Eye Fed Meeting for Fresh Cues as US Equity Futures Edge Higher Pre-Bell
31/23/31
MT
Morgan Stanley Cuts Price Target on PetMed Express to $7 From $10 After Fiscal Q2 Miss, Keeps Underweight Rating
31/23/31
MT
Top Premarket Decliners
31/23/31
MT
Transcript : PetMed Express, Inc., Q2 2024 Earnings Call, Oct 30, 2023
31/23/31
Earnings Flash (PETS) PETMED EXPRESS Reports Q2 Revenue $71M, vs. Street Est of $76M
31/23/31
MT
PetMed Express, Inc. Makes Decision to Suspend the Quarterly Dividend Effective the Quarter Ended September 30, 2023
31/23/31
CI
PetMed Express, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
31/23/31
CI
Morgan Stanley Adjusts Price Target on PetMed Express to $10 From $17, Maintains Underweight Rating
19/23/19
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, supplies and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile applications. Its product line contains approximately 15,000 SKUs of pet medications, health products, and supplies. The Company offers various pet supplies, including food, beds, crates, stairs and other pet supplies. PetMeds products include Non-Prescription Medications (OTC) and supplies, and Prescription Medications (Rx). OTC and supplies include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. Rx includes heartworm and flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications.
More about the company
Last Close Price
4.26
USD
Average target price
7.75
USD
Spread / Average Target
+81.92%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1